The study compares the in vitro activity of the newest Fluoroquinolones; gatifloxacin and moxifloxacin with levofloxacin and ciprofloxacin using three major respiratory pathogens, Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.